Table 7.
Incremental cost effectiveness analysis of chronic hepatitis B treatments
| Treatments | Total cost (TL) | YLL | Cost difference (TL) | Year difference | ICER |
|---|---|---|---|---|---|
| TDF | 119,604 | 2.06 | |||
| ETV-TDF | 161,642 | 2.13 | 42,037 | 0.07 | Dominated |
| ETV | 162,115 | 2.13 | 42,511 | 0.07 | Dominated |
| LdT-TDF | 138,182 | 3.05 | 18,577 | 0.99 | Dominated |
| 3TC-TDF | 132,157 | 3.20 | 12,552 | 1.14 | Dominated |
| LdT | 151,059 | 4.10 | 31,455 | 2.04 | Dominated |
| 3TC | 147,245 | 6.52 | 27,640 | 4.56 | Dominated |
Calculations were done according to the constructed 40-year treatment model